Japan, March 26 -- LENTIGEN TECHNOLOGY INC has got intellectual property rights for 'COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD19/CD20 IMMUNOTHERAPY.' Other related details are as follows:
Application Number: JP,2024-180515
Category (FI): A61K31/7088,A61K35/17,A61K40/11,A61K40/31,A61K40/42,A61K48/00,A61P35/00,C07K16/28,C07K19/00,C12N15/113@Z,C12N15/12,C12N15/62@Z,C12N15/63@Z,C12N15/861@Z,C12N15/864,100@Z,C12N15/867@Z,C12N15/869@Z,C12N15/86@Z,C12N5/0783,C12N5/10
Stage: Grant (IP right granted following substantive examination.)
Filing Date: Oct. 16, 2024
Publication Date: Feb. 12, 2025
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication....